PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study ...
SAN FRANCISCO, Aug. 26, 2022 /PRNewswire/ -- ProSomnus Sleep Technologies ("ProSomnus"), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today ...
SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision oral appliance therapy (OAT) for the treatment of Obstructive Sleep Apnea (OSA), ...
ProSomnus (NASDAQ: OSA) is a leading CPAP alternative for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with ...
ProSomnus is honored to partner with Lovell to expand access to Precision Oral Appliance Therapy for the millions of Veterans with Obstructive Sleep Apnea.” — Len Liptak, CEO, ProSomnus Sleep ...
SAN FRANCISCO--(BUSINESS WIRE)--ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy ® and pioneer in Smart Sleep Medicine™, today announced a ...
Most of the patients mild-to-moderate patients were treated to an apnea-hypopnea index of fewer than 10 events per hour. After a minimum one-year follow-up period, 96% of patients continued using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results